It is a masking effect—often caused by surfactants (like Polysorbate) and chelators (like Citrate)—where endotoxins become undetectable by traditional LAL tests, posing a significant risk to patient safety. Key Takeaways from TR 82:
For a new drug application (NDA/BLA), include the TR 82 data in Module 3 (Quality). For existing products, be prepared for a Standards of Care expectation during the next FDA or EMA audit.
Review all marketed and pipeline parenteral products. Flag any containing polysorbates (20 or 80), Cremophor, cyclodextrins, or EDTA. pda technical report 82
It sounds like you’re looking for a from PDA Technical Report No. 82 (TR-82) , titled “Low Endotoxin Recovery” (published 2020).
The measurement of solid content typically involves techniques such as: It is a masking effect—often caused by surfactants
This article is for informational purposes only. Refer to the official PDA Technical Report No. 82 (2018) for complete guidelines and consult with regulatory authorities for specific product requirements.
, published in March 2019, provides comprehensive guidance on Low Endotoxin Recovery (LER) . LER is a phenomenon where endotoxins in certain drug formulations (typically biologics) become "masked," making them undetectable by standard compendial tests like the Limulus Amebocyte Lysate (LAL) assay. Core Objectives of TR 82 Review all marketed and pipeline parenteral products
PDA Technical Report No. 82 (TR 82), titled Low Endotoxin Recovery (LER)